Gubra is a hybrid CRO and R&D company with proprietary target and drug discovery programmes focusing mainly on metabolic and fibrotic diseases. At Gubra, RNA sequencing (RNAseq) is a cornerstone technology for nearly all purposes whether it be evaluating drug effects in a preclinical disease model, identifying new drug targets in different disease areas or unravelling cell-type specific molecular signatures of human disease progression.

In this talk, we will describe how RNAseq is an increasingly valuable tool in Gubra’s CRO platform and how we make large-scale and complex transcriptomic information available and actionable to end users. We exemplify why transcriptomics plays a key role in the development of our target discovery platform PreDict, enabling identification of novel therapeutic targets across different tissues and diseases. Finally, we demonstrate the value of performing single nuclei RNAseq on liver needle biopsies to gain cell-type resolved understanding of disease progression in patients with non-alcoholic steatohepatitis (NASH).